NAD+ for Heart Health & Heart Failure: The Evidence

NAD+ has a genuinely plausible cardiac story behind it. The heart is one of the most energy-hungry organs in the body, it runs almost entirely on mitochondrial ATP, and failing hearts show disrupted NAD+ metabolism. That biology has launched a wave of marketing — NAD+ IV drips and NMN capsules pitched for "heart health" and "cardiovascular longevity." But the honest gap between that mechanism and proven human benefit is wide. There is now a first, encouraging randomized trial in heart-failure patients — and reading it carefully shows exactly why "promising" and "proven" are not the same word. Here's what the evidence actually supports.

The mechanism: why the heart is an NAD+ story at all

The rationale isn't hype on its face. NAD+ is the central coenzyme of energy metabolism, shuttling electrons through the reactions that let mitochondria make ATP — and the heart's relentless contraction makes it utterly dependent on that supply. In experimental models, NAD+ levels fall in the failing heart, and restoring them protects cardiac function. The most cited demonstration: in a mouse model of dilated cardiomyopathy, nicotinamide riboside (an NAD+ precursor) preserved cardiac function and blunted the disease's progression ¹. Reviews of NAD+ metabolism in cardiovascular disease lay out the same throughline — NAD+ decline, mitochondrial dysfunction, and inflammation feed heart disease, making NAD+ repletion a rational target ².

That's a strong mechanistic case. But mechanism is where cardiology graveyards are full — countless agents that fixed a pathway in mice did nothing, or harm, in people. So the only question that matters is what controlled human trials show.

The 2026 human trial: real signal, real limits

The headline development is the first randomized controlled trial of NAD+ in ischemic heart failure. Researchers enrolled 180 adults with ischemic cardiomyopathy (ejection fraction ≤45%, NYHA class II–III) and randomized them to intravenous NAD+ or placebo for 7 days, on top of standard guideline-directed therapy, with follow-up to 6 months ³.

The primary endpoint moved: at one month, left-ventricular ejection fraction was significantly higher in the NAD+ group than placebo (about 45.4% vs 42.4%, p = 0.024) ³. More NAD+-treated patients also improved their NYHA functional class. That is a genuine, placebo-controlled positive result — the first of its kind for NAD+ in heart failure.

But read the rest of the numbers, because this is where honesty matters. The reduction in NT-proBNP (a key heart-failure blood marker) was only a trend and did not reach statistical significance (p = 0.102) ³. The drop in 6-month major adverse cardiac events and in heart-failure hospitalizations also only trended lower without reaching significance (roughly 14.6% vs 24.7% for the composite, p = 0.089) ³. In plain terms: the trial showed a modest, real improvement in a heart-function measurement, but it did not prove NAD+ keeps people with heart failure out of the hospital or alive longer. Those are the outcomes patients actually care about, and they remain unproven.

It's also one single-center trial of 180 people, using a brief 7-day intravenous course — not an oral supplement, and not the kind of large, multi-center, hard-outcome trial that changes guidelines. It is a reason for cautious optimism and more research, not a green light to treat heart failure with NAD+.

What the precursor (NR) trials add

The other strand of human evidence comes from nicotinamide riboside (NR) in heart failure. A randomized trial gave NR (1,000 mg twice daily) for 12 weeks to people with heart failure with reduced ejection fraction; it roughly doubled whole-blood NAD+ and was safe and well tolerated ⁴. Encouragingly, the rise in NAD+ correlated with improved mitochondrial respiration in blood cells and lower expression of the NLRP3 inflammasome — a mechanistic hint that the pathway engages in humans ⁴. But the authors are explicit that the study was a safety and tolerability trial, not powered for clinical outcomes ⁴. An earlier study likewise confirmed NR safely raises NAD+ in heart-failure patients without major adverse effects ⁵. So the human NR data establishes feasibility and safety — it does not establish that NR makes failing hearts work better in ways patients feel.

Where the marketing outruns the evidence

This is the crucial divide for anyone reading drip-clinic or supplement copy. NAD+'s cardiac evidence is real but confined to: a single small RCT showing an ejection-fraction improvement with IV NAD+ in ischemic heart failure ³, plus safety/mechanism data for NR in heart failure ⁴⁵, plus protective findings in animals ¹. What does not exist is any trial showing NAD+ or its precursors prevent heart attacks, lower cardiovascular mortality, or improve heart health in people without heart failure. Claims that NMN or NAD+ IVs are "cardioprotective" for healthy adults are extrapolation from animals and mechanism — the kind of leap that, in cardiology, frequently fails to pan out. NMN reliably raises blood NAD+ in people ⁶ and slows decline in aged mice ⁷, but neither is a cardiovascular outcome.

If you have heart disease, the practical bottom line is blunt: NAD+ is not a substitute for guideline-directed heart-failure therapy, and even in the one positive trial it was given on top of that therapy ³. Talk to a cardiologist before adding anything.

Bottom line

The heart is a legitimate NAD+ target, and 2026 brought the first randomized human evidence that IV NAD+ can modestly improve ejection fraction in ischemic heart failure ³. That's a real milestone — but it's one small, short, single-center trial whose harder endpoints (NT-proBNP, hospitalizations, mortality) only trended and were not proven ³. The NR data shows the precursor is safe and engages the pathway in heart-failure patients, without yet proving clinical benefit ⁴⁵. For healthy people, there is no trial evidence that NAD+ protects the heart. Treat it as a promising research direction, not a proven cardiac therapy. For the broader evidence picture, see our pillar guide to NAD+ therapy; for the related questions of whether NAD+ delivers more energy or slows aging; and for where products land overall, the best NAD+ supplements.